ArticleNano-micro letters2022
A Sub-Nanostructural Transformable Nanozyme for Tumor Photocatalytic Therapy.
Article in Nano-micro letters, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 53 citations in OpenAlex.
- Deciphering the Catalytic Mechanism of Oxidoreductase-Like Nanozymes Along the Reaction Pathway: Activity, Specificity and Sustainability.Advanced materials (Deerfield Beach, Fla.) · 2026Review
- Recent advances on nanozyme-driven technology for detecting pharmaceutical and toxic molecules.Analytical and bioanalytical chemistry · 2026Review
- One-Pot Synthesis of Oxygen Vacancy-Rich Amorphous/Crystalline Heterophase CaWOAdvanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Advancements in research on the precise eradication of cancer cells through nanophotocatalytic technology.Frontiers in oncology · 2025Review
- Amoeba-Inspired Soft Robot for Integrated Tumor/Infection Therapy and Painless Postoperative Drainage.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- Catalytic Dual-Mode Immunotherapy: Anisotropic AuPt Heterostructure Decorated with Starry Pt Nanoclusters for Robust Cancer Photometalloimmunotherapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- Engineering tumor-oxygenated nanomaterials: advancing photodynamic therapy for cancer treatment.Frontiers in bioengineering and biotechnology · 2024Review
- Recent Developments in Metallic Degradable Micromotors for Biomedical and Environmental Remediation Applications.Nano-micro letters · 2023Review
- A Stable Open-Shell Conjugated Diradical Polymer with Ultra-High Photothermal Conversion Efficiency for NIR-II Photo-Immunotherapy of Metastatic Tumor.Nano-micro letters · 2023Article
- Cerium End-Deposited Gold Nanorods-Based Photoimmunotherapy for Boosting Tumor Immunogenicity.Pharmaceutics · 2023Article
- Mace-Like Plasmonic Au-Pd Heterostructures Boost Near-Infrared Photoimmunotherapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023Article
- Applications of Nanomaterials in Dentistry: A Review.Journal of International Society of Preventive & Community DentistryReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The structural change-mediated catalytic activity regulation plays a significant role in the biological functions of natural enzymes. However, there is virtually no artificial nanozyme reported that can achieve natural enzyme-like stringent spatiotemporal structure-based catalytic activity regulation. Here, we report a sub-nanostructural transformable gold@ceria (STGC-PEG) nanozyme that performs tunable catalytic activities via near-infrared (NIR) light-mediated sub-nanostructural transformation. The gold core in STGC-PEG can generate energetic hot electrons upon NIR irradiation, wherein an internal sub-nanostructural transformation is initiated by the conversion between CeO
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.